Objective: The aim of this study is testing the value of H-FABP in the early diagnosis of ACS alone or with routinely used biomarkers such as myoglobin, CK-MB, and cTn I in patients who admitted to emergency department (ED) with complaint of chest pain and suspected acute coronary syndrome. Material and Methods: This prospective and cross-sectional study was performed at the Emergency Department of University hospital between June 2009 and September 2010. Patients who were admitted with chest pain within first 48 hours and suspected ACS were enrolled to the study. Blood samples were taken for CK-MB, myoglobin, cTnI and H-FABP The patients were divided into two groups (ACS and non ACS). Statistical analyse were used for relation of biomarkers with diagnosis of ACS. Results: A 66 patients were included to the study. H-FAPB values were positive in15.2% patients. When H-FABP was added to routinely used biomarkers in the diagnosis of ACS, increasing was observed in all sensitivity, specificity, PPV and NPV values. However, this increase was not stastistically significant. Conclusion: H-FABP did not provide any significant change in early diagnosis and exclusion of ACS diagnosis when used either alone or combination with routinely used biomarkers
Introduction:
Early diagnosis of acute coronary syndrome (ACS) is essential to prevent major complications and death. Routinely used biomarkers such as myoglobin, MB form of creatine kinase (CK-MB) and cardiac troponin-I (cTn I) can be detected at least 3 hours after chest pain and new biomarkers are needed Recent clinical and experimental studies have suggested that heart-type fatty acid-binding protein (H-FABP) is superior to CK-MB or cardiac troponins in early detection of ischemic myocardial necrosis (1, 2) . H-FABP is a low molecular weight (14.5 kDa) protein, which contains 132 amino acid residues (3). Fatty acid-binding proteins bind the long-chained fatty acids reversibly and noncovalently, facilitating the intracellular cytoplasmic transport of the fatty acids, and are highly expressed in tissues with active fatty acid metabolism such as the heart muscle (4, 5) . Its concentration in blood reaches the maximum within 6-8 h and generally decreases within 24-36 h (6). The aim of this study is testing the value of H-FABP in the early diagnosis of ACS alone or with routinely used biomarkers such as myoglobin, CK-MB and cTn I in patients who admitted to emergency department (ED) with complaint of chest pain and suspected acute coronary syndrome. and history of patients were noted and physical examination were done by researchers. Twelve-lead ECGs were taken in first 10 minutes of admission and blood samples were taken from antecubital vein in first 30 minutes for CK-MB mass, myoglobin, cTnI and H-FABP. Evaluation and the final diagnosis of patients were done according to ACC/ESC guidelines. (7, 8) The patients were divided into two groups. The patients with ST segment elevation on ECG and/or elevated cardiac biomarker levels were taken into group 1 (the patients with ACS diagnosis). The patients with non-specific ECG changes and/or negative cardiac biomarker levels were taken into group 2 (non-ACS diagnosis).
The H-FABP bedside test (Cardiodetect® Rennesens GmbH, Berlin) used in this study is a rapid chromatographic immunotest designed for qualitative determination of H-FABP. It consists of a sample pad (blood separator), a conjugate pad, a nitrocellulose membrane and an absorbent pad incorporated in a test card that has the size of a credit card. Immobilized on the membrane is a test line made of a specific capture monoclonal antibody for H-FABP and a second line, acting as control, consisting of anti-mouse IgG. The test is performed by drawing four drops of capillary whole blood from the patient's blood sample and applying them onto the teststrip. Within 15 minuntes the H-FABP test result (two red lines for elevated plasma H-FABP and one red line for non-elevated plasma H-FABP) can be read. Miyoglobin, CK-MB and troponin levels were measured at the laboratory of ED with Stratus CS device of Dade Behring Company. Reference range for myoglobin: 9-82 ng/mL, CK-MB mass: 0-3,6 ng/mL, cTnI: 0-0.1 ng/mL (Stratus CS Dade Behring, Germany) and H-FABP: 7 ng/mL (CardioDetect quant® (Rennesens GmbH, Germany)) were accepted. Information about prognosis of patients were taken by phone call three months after hospital discharge. SPSS 15.0 (SPSS Inc, Chicago, IL) and MedCalc 11.3 (MedCalc Software, Mariakerke, Belgium) statistical programmes were used for statistical analyses of data. ROC curve analyse were used for relation of biomarkers with diagnosis of ACS. Chi-square test was used for comparison statistics. Frequency was used for descriptive statistics for categorical variables. Mean ± SD for continuous variables fit a normal distribution and the median and IQR for variables that do not meet the normal distribution were used. p <0.05 were considered statistically significant.
Results:
Fifty two (78.8%) of 66 patients were male and fourteen (21.2%) were female. Mean age of the study population (Table 2) . When H-FABP was added to routinely used biomarkers in the diagnosis of ACS, increasing was observed in all sensitivity, specificity, PPV and NPV values. However, this increase was not stastistically significant (Table 3) . AUC value of H-FABP in the diagnosis of ACS was 0,61 (95%CI; 0,48 -0,73) and cTn I was 0,51 (95%CI; 0,52 -0,76) ( Figure 1 ). H-FABP reaches the highest concentration in four hours after cardiac injury. H-FAPB values were positive in 10% (n=5) of 50 patients who admitted to the emergency department within four hours of chest pain and 31,3% (n=5) of 16 patients who admitted to the emergency department more than 4 hours. There was a stastistically significant difference between first 4 hours admission and more than 4 hours admission in terms of positively of H-FABP (p<0,05). Forty-eight patients (72,7%) were reached by phone three months after hospital discharge. There was no mortality and morbidity 72,2% (n=26) of group 1 and 53,3 % (n=16) of group 2 and 13,9% (n=5) of group 1 and 3,3 % (n=1) of group 2 were died. Discussion Chest pain creates 5% of all ED admissions. Significant portion of the patients admitted to the emergency department with chest pain get diagnosis of ACS. 15% of admissions to the ED with chest pain are diagnosed with ACS (9,10). Patients are admitted to the ED without chest pain (47%), pricking and piercing chest pain (22%), and pleuritic chest pain (6%) (11) . In our study ACS prevalence was high. Patients suspected of having ACS were enrolled to the study and ACS prevalence was higher than literature. Liao et al (12) reported that 73% (n=74) of patients (with chest pain?) received a diagnosis of AMI; the mean age of patients was 69.0 years, and 70% of the study population was male. In our study, 54.5% of patients who were admitted to ED with chest pain were diagnosed with ACS; the mean age was 59.8 years, and 78.8% were male. Early diagnosis of AMI affects mortality directly; thus, biochemical biomarkers have been examined with regard to faster and more accurate diagnoses of AMI (12, 13) .
Several studies have shown that sensitivity and specificity of H-FABP ranged from 39 to 78.5% and 78.2 -94%, respectively in early diagnosis of ACS (14) (15) (16) (17) (18) (19) (20) . Orak et al (18) was found 98% specificity and 71% sensitivity different from those study. The most important cause of the different results in these studies which used qualitative techniques is thought to be the low cut-off levels. 100% sensitivity and 27-38% specificity were found in two studies which used quantitative H-FABP measurements like our study (21, 22) . Results of our study were consistent with literature which used quantitative H-FABP measurement. In addition, PPV and NPV values of our study were consistent with 63-100% PPV and 47-97% NPV values of literature (21, 22) . Diagnostic accuracy (AUC) of H-FABP ranges from 0,65 to 0,83 in the literature (15, 17) . In one study, AUC was determined as 0,967, but this is considered to low cut-off value (18) . In our study, the AUC values were consistent with the results of the literature. Freund et al (17) found that sensitivity, specificity, PPV and NPV values of troponin were 71%, 97%, 78% and 95% respectively and these values were 80%, 85%, 46% and 96% for troponin used together with H-FABP.
Mc Mahon et al (23) found that sensitivity, specificity, PPV and NPV values of troponin within first six hours were 67.6%, 94.3%, 66% and 95% respectively, and these values were 88.2%, 86.8%, 52% (14) reported that H-FABP is not ideal test and has high false negativity, also is not appropriate for exclusion of a disease with high morbidity and mortality such as ACS. In our study, CK-MB and H-FABP was not superior to each other in early diagnosis of ACS. In addition, specificity and PPD of H-FABP results were better than cTn I results on admission. When compared CK-MB, H-FABP did not show significant contribution to early diagnosis of ACS.
Limitations
The most important limitation of our study is the low number of cases and to be a single center trial. Ischemic type chest pain was used to selection of the patients and this was a limitation in terms of homogenization. Quantitative measurement of H-FABP in our study was the other limitation.
Conclusion
Consequently we did not found significant change in early diagnosis and exclusion of ACS diagnosis when used either alone or combination with routinely used biomarkers such as myoglobin, CK-MB and cTnI. Further studies with large study population should be performed.
